Alkermes to Present Data for ALKS 2680 in Narcolepsy Treatment
Alkermes will present new data for its investigational narcolepsy treatment, ALKS 2680, at SLEEP 2024 in Houston.
Source: sleepreviewmag.com
Stay updated with breaking news from Michaelj Doane. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Alkermes will present new data for its investigational narcolepsy treatment, ALKS 2680, at SLEEP 2024 in Houston.
- Late-Breaking Abstracts Containing Data From the Full Narcolepsy Type 1 Cohort From the ALKS 2680 Phase 1b Study and Vibrance-1 Phase 2 Study Design Accepted for Poster Presentations - -